Anti-CGRP Monoclonal Antibodies for Treating Nausea and Vomiting Including CINV
Summary
The USPTO published patent application US20260098082A1 for methods using anti-Calcitonin gene related peptide (CGRP) monoclonal antibodies to treat nausea and vomiting, including chemotherapy-induced nausea and vomiting (CINV). The application, filed September 13, 2023, claims methods of preventing and counteracting CINV by targeting CGRP, a neuropeptide associated with emetic responses to chemotherapy and other triggers.
What changed
The USPTO published a patent application claiming methods of treating nausea and vomiting using anti-CGRP monoclonal antibodies. The claims cover direct administration of anti-CGRP antibodies for preventing and counteracting chemotherapy-induced nausea and vomiting triggered by antitumor chemotherapeutics and other emetogenic agents. The antibodies target CGRP, a neuropeptide with pleiotypic effects implicated in emetic pathways.
Pharmaceutical and biotechnology companies developing CGRP-targeting therapies should monitor this application for potential freedom-to-operate concerns. The publication represents a method-of-treatment claim that could affect competitive positioning in the antiemetic and supportive care space. Clinical investigators studying CINV management may benefit from understanding the emerging patent landscape around CGRP blockade approaches.
What to do next
- Monitor patent prosecution status
- Review claims for freedom-to-operate
- Evaluate licensing opportunities
Archived snapshot
Apr 12, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MODULATORS OF NAUSEA AND VOMITING
Application US20260098082A1 Kind: A1 Apr 09, 2026
Inventors
Alberto CHIARUGI
Abstract
A method in which anti-Calcitonin gene related peptide (CGRP) monoclonal antibodies are used for direct treatment of nausea and for vomiting, including chemotherapy-induced nausea and vomiting (CINV) induced by multiple triggers. Among them, drugs frequently prompt nausea and vomiting, such as antitumor chemotherapeutics which are among the most emetic drugs and often cause CINV, which in turn can severely compromise efficacy of therapy, as well as patient quality of life. The method uses anti-CGRP monoclonal antibodies to target calcitonin gene related peptide (CGRP), a neuropeptide with pleiotypic effects in the human body, to prevent and counteract CINV.
CPC Classifications
C07K 16/18 C07K 16/28
Filing Date
2023-09-13
Application No.
19111781
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.